GT Biopharma (GTBP) investor relations material

Executive summary

• Focused on developing TriKE® and Dual Targeting TriKE® immuno-oncology platforms targeting hematologic malignancies and solid tumors, with multiple candidates in clinical and preclinical stages.

• GTB-3650 and GTB-5550 are actively enrolling patients in Phase 1 trials, with first patients dosed and multiple cohorts enrolled; updates expected in the second half of 2026.

• Integration of AI-based tools is accelerating discovery and engineering of new tumor-targeting candidates, with multiple assets expected to move toward pre-IND development in 2027.

• No product sales or revenue; operations funded by equity and warrant issuances.

Financial highlights

• Net loss for Q2 2026 was $4.5M, a significant improvement from $30.2M in Q2 2025, mainly due to the absence of a $28.7M Greenshoe Rights liability.

• Operating expenses rose to $4.5M for Q2 2026, up 198% year-over-year, driven by higher R&D and SG&A costs.

• Cash and equivalents at June 30, 2026 were $5.1M, expected to fund operations through Q4 2026.

• Net cash used in operations was $6.7M for the first half of 2026.

Outlook and guidance

• Substantial doubt exists about the ability to continue as a going concern within one year without additional financing.

• Updates on both GTB-3650 and GTB-5550 clinical programs are anticipated in the second half of 2026.

• IND clearance for an additional TriKE® pipeline asset is anticipated in 2026.